Key result
The 2017 US guidelines recommend a target blood pressure of <130/80 mm Hg, supporting the earlier use of fixed-dose combination therapies like amlodipine and olmesartan to improve blood pressure control.
Why the study?
Does combination therapy with amlodipine and olmesartan improve blood pressure control and reduce cardiovascular complications in patients with arterial hypertension?
Does combination therapy with amlodipine and olmesartan improve blood pressure control and reduce cardiovascular complications in patients with arterial hypertension?
Answers are grounded in this paper and cite their sources.
The 2017 US hypertension guidelines lower the target BP to <130/80 mm Hg, highlighting the importance of fixed-dose combination therapies like amlodipine and olmesartan for effective BP control.
The key goal in the treatment for patients with AH is to reduce the risk of cardiovascular complications through reaching the target level of arterial pressure (AP) and organ protection, treatment of concomitant diseases and correction of risk factors. The new US guidelines for the management of hypertension indicate that the target blood pressure level for all patients was less than 130/80 mm Hg. This is due, among other things, to changing the blood pressure levels classification and categorizing all adults with blood pressure of 130/80 mm Hg. and higher as having hypertension. The need for not only wider combination therapy for the treatment of hypertensive patients, but also its earlier commencement has been strongly confirmed by these new guidelines for the management of AH. The wider use of combinations, especially in fixed doses, such as the calcium channel blocker amlodipine, and the angiotensin II receptor antagonist olmesartan for the treatment of hypertension, will help improve blood pressure monitoring, reduce the risk of complications and increase the AH patients’ life expectancy.
No takes yet. Share an insight, caveat, or question.
Karpov IuA (2018) conducted a review in Arterial hypertension. Amlodipine and olmesartan combination therapy was evaluated. The 2017 US guidelines recommend a target blood pressure of <130/80 mm Hg, supporting the earlier use of fixed-dose combination therapies like amlodipine and olmesartan to improve blood pressure control.
Synapse has enriched 10 related papers. Consider them for comparative context: